Development of the Sm14/GLA-SE - schistosomiasis vaccine candidate: An open, not placebo-controlled, standardized dose immunization phase Ib clinical trial targeting healthy young women

Vaccine Antigen and Adjuvant

For the studies carried out in rabbits as well as the clinical trial, the Sm14 vaccine used in the study was produced at the Ludwig Institute for Cancer Research (LICR) and Cornell University, NY, USA under Good Manufacturing Practice conditions (cGMP). Hermetically closed vials, with individual doses (0.55 mL), labelled with product name, Sm 14, lot number (PBR-0057-002), date of manufacture and “only for investigational use”, were shipped to Brazil under the import authorization from the National Council for Scientific and Technological Development (CNPq) and the Anvisa. Vials were kept at 2-8°C under continuous temperature control from the origin at Fiocruz (Rio de Janeiro) until use, with regular inspections assuring contents remaining liquid and transparent without suspended particles.

The Infectious Diseases Research Institute/ Access to Advanced Health Institute (IDRI/AAHI) provided the Glucopyranosyl Lipid-A adjuvant in Squalene Emulsion (GLA-SE) vials containing 0.4 mL, at a concentration of 40 µg/mL, also produced under GMP conditions, labelled with lot number (Part # 0037-09M001) and manufacturing date. Shipping and storage followed the same procedures as described above.

The batches of Sm14 and adjuvant were filled finished as single doses and mixed at the moment of immunizations.

To formulate the vaccine antigen dose at the time of administration, 0.4 mL of a 200µg/mL Sm14 suspension were aspirated using a 1 mL sterile syringe. Subsequently, the volume of the syringe was injected into the vial containing the GLA-SE adjuvant, obtaining a total volume of 0.8 ml mixture. After mixing by inverting the vial, 0.5 mL containing 50µg of Sm14 protein and 10µg adjuvant was administered by intra-muscular route to both animals and women volunteers. The dose used in these studies were based on a clinical protocol approved by Anvisa for the Phase Ia study in male volunteers [22]. The two components of the vaccine candidate, kept in separate vials, were monitored by Pharmaceutical Product Development (PPD) [23]. Samples were sent to PPD for control every three months in accordance with applicable standard operating procedures and the US Food and Drug Administration (FDA) regulations. Stability of the Sm14 GMP lot was followed by PPD and updated “Certificate of Analysis” issued.

Pre-clinical experiments on safety and immunogenicity of pregnant rabbits and respective off springs, following Sm14 vaccination in the mothers

The study in pregnant rabbits was conducted in accordance with the protocol provided by Anvisa. It was reviewed and approved by the Ethics Committee on Animal Research of Fiocruz (CEUA/Fiocruz) n° L0063/08 – LW 19/2013.

The reproductive toxicity tests were performed with the same vaccine lot further used in Phase I Clinical Trials, which was produced under current good manufacturing practice (cGMP) conditions by LICR/Cornell University, NY, USA. Vials containing individual doses (0.55 mL, 200 µg/mL) were labelled with the product name (Sm14) and lot number (PBR-0057-002). Vials were kept at +2-8°C under continuous temperature control until use, with regular inspections to assure that the contents remained liquid and transparent without suspended particles.

Twenty-four NZW pregnant rabbits, with the same age and weight at the beginning of the experiment, were divided into two groups just after mating: one group comprising 12 rabbits immunized with three equal doses of 50 µg Sm14+10 µg GLA-SE/dose, with a 7-day interval between doses; and the control group, comprising 12 rabbits injected with PBS, same days intramuscularly. Injections of 0.5 mL/dose for each dose schedule were at the external middle third of the right and left thigh alternately, and administered on days 0 (day 9 of pregnancy), 7 (day 16 of pregnancy), and 14 (day 23 of pregnancy). The pregnancy period of these animals is approximately 30 days. Necropsy and anatomopathological evaluations were performed on day 29 of pregnancy.

All animals had the inoculation area shaved and marked before each immunizing dose, to assess further possible local reactions that might include erythema and edema; both being scored according to standard protocols [24]. Daily clinical evaluation of each animal was performed and duly recorded in the individual data chart by a veterinarian. Parameters such as occurrence of abortion, stress level, appetite, manure, and skin/local reactions at inoculations sites, were evaluated and measured. Body weight was determined at the beginning and at the end of the study. Food and water consumption was recorded every day individually.

Biochemical and blood cell evaluation was done following current laboratory practices and included liver, renal and pancreatic functions, as well as red and white blood cell countings and coagulation parameters.

All animals were anesthetized with thiopental sodium and euthanized by exsanguination. Detailed anatomopathological analyses of all organs were carried out following euthanasia. All animals were subjected to a macroscopic inspection of the organs and cavities. Samples of organs were collected in buffered 10% formalin for later microscopic analysis. The ovaries, uteri, and fetuses were collected and fixed for further analysis, such as number, size, weight, corpora lutea, placenta and living fetuses. Paraffin-embedded tissue sections were stained with hematoxylin and eosin (H&E) and examined under a light microscope [25].

Serum samples were collected from all rabbits before the start of pregnancy and on the date of euthanasia. The total anti-Sm14 IgG antibody titers in rabbit sera samples were determined by ELISA [26] in accordance with previously described procedures [27]. Briefly, the wells were coated overnight at 4°C with 100 µL/well of Sm14 protein solution at 4 µg/mL in carbonate buffer 0.1 M pH 9.6, blocked for 1h at 37°C, and then serum samples were added in two-fold serial dilution from 1/100 up to 1/1600. After washing, peroxidase conjugated goat anti-rabbit total IgG specific to the gamma chain (Santa Cruz Biotechnology, USA) was added to each well, and the plates were incubated for 1h at 37°C. Wells were washed and the reaction was developed by the addition of TMB substrate (Sigma-Aldrich, T0440) for 15 min at room temperature in the dark followed by the addition of Stop reagent (Sigma-Aldrich S5814); subsequently, the OD at 450 nm was measured using a BIORAD device, Model 680.

All statistical analyses were carried out by using GraphPad Prism version 4.0 software. All analyses were conducted by applying the two-tailed test, with p-values below 0.05 considered to be significant.

Phase Ib clinical trial in healthy women

The methodology used to conduct the Sm14+GLA-SE candidate vaccine Phase 1b clinical trial in women was essentially the same described by Santini-Oliveira et al. [22] for Phase 1a with healthy male adults (CE # 990768/10-8 - CAAE 0018.0.009.000-10). The protocol for the Phase Ib trial was approved by Anvisa (CE# 0577594139) and by the Evandro Chagas Review Council of the National Institute of Infectious Diseases (INI), Fiocruz (CAAE 09627212.4.0000-5262). In addition, tests were monitored by TECHTRIALS, an independent research company, and data was deposited into a Data Bank [28] under the code NCT01154049.

Twenty healthy female volunteers from a non-endemic area of Brazil (City of Rio de Janeiro) were enrolled and registered under numbers from #1 to #20. Among them, 10 were selected and went up to the end of the study. Inclusion criteria comprised negative pregnancy test, availability during the whole duration of the trial, no evidence of any acute infection, no previous or ongoing serious chronic disease, normal findings for organ functions as demonstrated by laboratory tests and physical examination of the cardio-respiratory and brain/neurological, abdominal organs, skin, and lymphatic system. Exclusion criteria included pregnancy/breast feeding, abnormal hematology or blood chemistry counting or data, any kind of ongoing infection, including infection by the human immunodeficiency virus (HIV), any chronic disease, alcohol/drug abuse or history of medication or vaccination in the preceding month. After clinical screening, the 10 participants aging 26-48 years (mean=36.3, sd=6.8) were selected for the trial, and their demographic characteristics are depicted in S1 Table.

Full physical examens and laboratory tests were done on baseline and days 0, 7, 30, 37, 60, 67, 90 and 120 (Supplemental figure 1). Participants were monitored at the site up to one hour after vaccination and followed-up by phone 20-28 hours afterwards. According to Santini-Oliveira [22], all adverse episodes were evaluated in compliance with the International Centers for Tropical Disease Research network (ICTDR), and according to the degree of severity as follows: Level 1 (tolerable with mild discomfort and not interfering with regular activities); Level 2 (discomfort with the impairment of regular activities but not requiring any specific medical assistance, or treatment); Level 3 (requiring discharge of regular activities and medical intervention) and Level 4 (life threatening). The laboratory at the Evandro Chagas National Institute of Infectology (INI) is certified by the College of American Pathologists (CAP, EUA) and laboratory tests were evaluated based on the INI Standard Values Chart. The study followed FDA regulations [29].

Samples of peripheral blood mononuclear cells (PBMCs) and of sera were collected from all subjects on baseline and days 0, 30, 60, 90 and 120. Immediately after collection, PBMCs were separated by centrifugation at room temperature in Ficoll-Paque Plus (GE Healthcare, USA) and mixed with Fetal Bovine Serum (FBS) (Gibco Life Technologies, USA) and 10% DMSO. Cells were subsequently transferred to 2 mL cryovials and frozen down to −80°C in a NALGENE ™ Cryo 1°C freezing container (Nalgene, USA) overnight. On the following day vials were transferred to liquid nitrogen and later dry shipped to the Infectious Disease Research Institute (IDRI, Seattle, USA) where they were stored in liquid nitrogen until use.

Sera were also stored in Brazil at −80°C and transferred in dry ice to IDRI for analysis. At IDRI, sera were stored at −80°C, till experiments were performed. The immunogenicity analyses included isotype check of anti-Sm14 antibodies and cell-mediated responses specifically induced after vaccination with Sm14+GLA-SE. It also included detection and quantification of intracellular cytokines after stimulation of PBMCs with purified rSm14. Immune cell responses were measured using the PBMC Luminex Kit for T cell cytokines (Milliplex ®MAP) [22]. Isotyping and the correlation between the development and the size of humoral response measured in terms of IgG against the Sm14 protein were done by enzyme-linked immunosorbent assay ELISA [22,26].

Descriptive analysis using IBM SPSS v20 statistical package was performed for all variables. Boxplots for all follow-ups assessed whether observations were outside the limits specified for specific laboratory tests. Proportions of adverse events and 95% confidence intervals were calculated using Clopper-Pearson method [30]. For toxicity grading scales, we used limit values based on published information when available, which included clinical experience and reviewed vaccine clinical trials on healthy subjects. Toxicity grading scales were based on the local laboratory reference values when those were defined. Statistical analyses of immunogenicity data were performed using analysis of variance, followed by Tukey’s test for multiple comparisons.

The statistical analysis was done based on the evaluation of local and systemic reactogenicity observed in the first 36 hours after each dose of the vaccine. Results of chemical and hematological exams were compared to reference values in accordance with the Richet Laboratory (LR) criteria and ICTDR, including levels of toxicity as defined by FDA [29].

Sm14 vaccine candidate does not induce any toxicological effect in pregnant rabbits

The body weights and structures of the analyzed organs in all pregnant rabbits, irrespective of being or not vaccinated were within normal limits, according to established criteria [31]. Macroscopic analysis of organs and cavities revealed results consistent with the usual aspects for normal pregnant rabbits [32]. The ovaries of all 24 animals were consistent with normal appearance. All analyzed uteri were comparable with a normal pregnant uterus for outbred rabbits according to established criteria [33]. The microscopic results showed that the ovaries of all 24 pregnant rabbits had follicles at different stages of development in the cortical region, usual interstitial stromal glands and containing varying numbers of corpora lutea (Figure 1). There was no statistically significant difference for any of the parameters assessed in this study between vaccinated and control animals. Table 1 shows that the duration of pregnancy, the number of implantation sites in the uterus, and the number and viability of pups guarantee the absence of maternal and embryo-fetal toxicity in pregnant rabbits vaccinated with Sm14+GLA-SE. The results were also consistent with the morphological and physiological aspects reported for farmed NZW rabbits [31–33].

• Download figure
• Open in new tab

Fig 1. Normal macroscopic and microscopic views of an ovary from a Sm14/GLA-SE vaccinated pregnant rabbit.

Panel A depicts the normal macroscopic pattern of the ovary, showing multinodular outer surface and brownish with marked vessels. Panel B shows microscopic view with follicles in various stages of development in the cortical region (within the black circles). Corpora lutea (CL) can be seen in panel C whereas a higher magnification of a follicle can be seen in Panel D. Sections were stained with Hematoxylin-eosin. Scale magnification with the objectives for 40x (in panel B), 100x (in panel C) and 200x in panel D).

The skin and subcutaneous tissue were removed from the injection sites of the immunized animals. The results of the individual tests showed no significant histopathological alterations in the skin at the immunization site. In the anatomopathological evaluation of the organs, it was observed that all groups, including the control group, had small and scarce foci of calcification in 5% of the cortical and medullary tubules of the kidneys.

Lastly, ELISA was used to analyze sera collected from the animals after the final injection and showed considerably high production of the anti-Sm14 antibody in the sera of vaccinated versus non-vaccinated PBS-treated pregnant rabbits. Anti-Sm14 antibody levels (evaluated by optical density) were clearly high in the vaccinated group as compared to controls (Figure 2).

• Download figure
• Open in new tab

Figure 2. Total anti-Sm14 IgG antibody titers, determined by ELISA, of all rabbit serum samples from the two groups in the reproductive toxicity study.

OD: optical density.

Sm14 vaccine candidate does not induce any major adverse effects (AEs) in healthy women

The certification of Sm14+GLA-SE vaccine safety in this preclinical study paved the way for the phase Ib clinical trial of the vaccine in young adult non-pregnant women. The candidate vaccine Sm14+GLA-SE was shown to be safe with no serious adverse events as observed in the participants after any of three doses. No local reactions at the site of the injection occurred, except for local pain which affected 9 out of 10 women after the first dose, 5 out of 9 after the second, and 4 out of 10 after the third (all lasting less than 24 hours after injection). Only one subject reported involuntary muscle contractions lasting 5 minutes near the site of infection after the first dose. Table 2 shows the adverse events associated with vaccination of the healthy female volunteers in the Phase Ib.

With regards to systemic adverse events, two participants had fever at D7, and two others had light local hyperemia and headache at D37, probably related to the vaccine. Physical exams on all days (baseline, 0, 7, 30, 37, 60, 67, 90, and 120) showed no clinical alterations or abnormalities. Laboratory exams did not show alterations that could be classified as toxicity according to the ICTDR criteria, except for ALT and GGT, with few participants showing elevated values within toxicity levels. However, these participants also had elevated values prior to the vaccination (at baseline), and since they had no other abnormal laboratory findings or clinical symptoms, they were considered as most probably not related to the vaccine. All other single instances of values outside of the normal range were evaluated and, given that no abnormal laboratory findings or clinical symptoms were observed, they were all considered as non-clinically significant (that is, most probably not related to the vaccine). These data show that the vaccine produced very few adverse effects and all the observed events were local and mild (Tables 3 and 4).

Sm14 does induce adaptive immune responses in healthy women

As occurred with male subjects on Phase IA [22], the immune response of females vaccinated with the Sm14+GLA-SE was characterized by high levels of anti-Sm14 IgG, mainly of the IgG₁ isotype. Responses were augmented after the second dose. Ninety percent of vaccinated subjects developed higher specific total IgG antibody titres 90 days post vaccination and theses titres remained as high up to 120 days. Compared to baseline, total specific IgG, as well as IgG₁ and IgG₃, increases were statistically significant from day-60 (Figure 3). The levels of specific IgG₂ and IgG₄ increased after the second dose and achieved statistical significance from day-90 up to day-120. Also, neither general nor specific IgE increases were detected at any time.

• Download figure
• Open in new tab

Figure 3. Levels of anti-Sm14 antibody classes and cytokine production stimulated by vaccination.

(A) ELISA antibody results (B) Percentage of CD4⁺ T cells expressing combinations of IFNγ, TNF_α and IL-2 production in CD4+ T cells on days 0, 30, 90 and 120. p-values for comparison was performed for vaccinated group to baseline (Day 0). *p-values at the 0.05 significance level.

The Sm14+GLA-SE vaccination elicited robust cytokine responses. Cytokine profiles show increased TNFα, IFNγ, and IL-2 in vaccinated individuals on days 90 and 120. Analysis results indicated overall comparable responses among male and female cohorts [22] (Fig 3).